Literature DB >> 21370438

Polycythemia in an infant secondary to granulocyte transfusions.

Olufolake Adisa1, Jeanne E Hendrickson, Courtney K Hopkins, Howard M Katzenstein, Cassandra D Josephson.   

Abstract

Granulocyte transfusions may be useful for neutropenic pediatric patients with refractory bacterial or fungal infections. Many potential adverse sequelae associated with granulocyte transfusions are well recognized, including febrile reactions, fluid overload, alloimmunization, and lung injury. Other potential adverse sequelae, however, are less well known. This case report describes an infant with familial hemophagocytic lymphohistiocytosis who developed polycythemia (hemoglobin 10-17.6 g/dl) following four daily transfusions of 20 ml/kg of apheresis collected, steroid stimulated donor granulocytes. Expanded knowledge of potential risks of transfused granulocytes will allow for rapid recognition of transfusion-related complications, should they occur.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21370438      PMCID: PMC3568762          DOI: 10.1002/pbc.23080

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.

Authors:  T H Price; R A Bowden; M Boeckh; J Bux; K Nelson; W C Liles; D C Dale
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

2.  Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis.

Authors:  E C Vamvakas; A A Pineda
Journal:  J Clin Apher       Date:  1996       Impact factor: 2.821

3.  Buffy coat and cell separator granulocyte concentrates. Comparison of cell content and in vitro granulocyte function.

Authors:  A Hughes; I E Addison; H Al-Hadithy; B Brozović
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

4.  Granulocyte transfusion therapy and amphotericin B: adverse reactions?

Authors:  J P Dutcher; J Kendall; D Norris; C Schiffer; J Aisner; P H Wiernik
Journal:  Am J Hematol       Date:  1989-06       Impact factor: 10.047

5.  Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils.

Authors:  Barbara J Bryant; Yu Ying Yau; Phyllis J Byrne; David F Stroncek; Susan F Leitman
Journal:  Transfusion       Date:  2010-01-22       Impact factor: 3.157

6.  Administration of G--CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G--CSF alone.

Authors:  D F Stroncek; Y Y Yau; J Oblitas; S F Leitman
Journal:  Transfusion       Date:  2001-08       Impact factor: 3.157

7.  Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients.

Authors:  C Peters; M Minkov; S Matthes-Martin; U Pötschger; V Witt; G Mann; P Höcker; N Worel; J Stary; T Klingebiel; H Gadner
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

8.  Pulmonary complications during granulocyte transfusions: incidence and clinical features.

Authors:  D D Karp; T J Ervin; S Tuttle; B C Gorgone; P Lavin; E J Yunis
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

9.  Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity.

Authors:  B W Dana; B G Durie; R F White; D W Huestis
Journal:  Blood       Date:  1981-01       Impact factor: 22.113

10.  Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases.

Authors:  Simone Cesaro; Pierangelo Chinello; Giustina De Silvestro; Piero Marson; Giorgio Picco; Stefania Varotto; Silvia Pittalis; Luigi Zanesco
Journal:  Support Care Cancer       Date:  2002-11-12       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.